Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL981807 | 0.92 | MDM4 (0.38) | ALDH1A1KMT2AMEN1L3MBTL1HSD17B10 | |
| SCHEMBL984581 | 0.92 | ALDH1A1 (0.44) | ALDH1A1KMT2AMEN1L3MBTL1HSD17B10 | |
| SCHEMBL985264 | 0.92 | MAPT (0.43) | ALDH1A1KMT2AMEN1L3MBTL1KDM4E | |
| SCHEMBL981263 | 0.91 | MDM4 (0.37) | ALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL986013 | 0.91 | MEN1 (0.46) | ALDH1A1KMT2AMEN1L3MBTL1HSD17B10 | |
| SCHEMBL986033 | 0.90 | CSNK2A2 (0.38) | HPGDLMNA | |
| SCHEMBL986034 | 0.90 | CSNK2A2 (0.38) | HPGDLMNA | |
| SCHEMBL983643 | 0.90 | MDM4 (0.36) | ALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL985561 | 0.90 | BTK (0.42) | ALDH1A1KMT2AMEN1L3MBTL1HPGD | |
| SCHEMBL984520 | 0.89 | MDM4 (0.37) | ALDH1A1KMT2AMEN1L3MBTL1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | claimed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | claimed |
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | ALDH1A1 924/4885KMT2A 2975/4885MEN1 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.